Abivax SA ((GB:0RA9)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abivax S.A. is currently conducting a Phase 2b clinical study titled ‘A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn’s Disease.’ The study aims to assess the efficacy and safety of obefazimod as an induction and maintenance therapy for patients with Crohn’s Disease who have not responded adequately to conventional or advanced therapies.
The intervention being tested is obefazimod, a drug administered once daily in varying doses (50mg, 25mg, and 12.5mg) to evaluate its effectiveness compared to a placebo in managing Crohn’s Disease symptoms.
This study follows an interventional design with randomized allocation and a parallel intervention model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are blinded. The primary purpose of the study is treatment-focused.
The study began on October 30, 2024, with an estimated completion timeline that includes a 12-week induction phase, a 40-week maintenance phase, and a 48-week extension phase. The last update was submitted on August 11, 2025, indicating ongoing recruitment and progress.
For investors, the progress of this study could significantly impact Abivax’s stock performance, especially if the results demonstrate positive outcomes for obefazimod. Success in this trial could position Abivax favorably against competitors in the Crohn’s Disease treatment market, potentially boosting investor confidence.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.